We are live on ! Find out more
IART icon

Integra LifeSciences

284 hedge funds and large institutions have $3.95B invested in Integra LifeSciences in 2022 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 113 increasing their positions, 95 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 23

19% more repeat investments, than reductions

Existing positions increased: 113 | Existing positions reduced: 95

2% more funds holding

Funds holding: 278284 (+6)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1.79% less ownership

Funds ownership: 89.7%87.92% (-1.8%)

16% less capital invested

Capital invested by funds: $4.71B → $3.95B (-$759M)

45% less call options, than puts

Call options by funds: $5.63M | Put options by funds: $10.3M

Holders
284
Holders Change
+6
Holders Change %
+2.16%
% of All Funds
4.78%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
35
Increased
113
Reduced
95
Closed
23
Calls
$5.63M
Puts
$10.3M
Net Calls
-$4.69M
Net Calls Change
-$6.92M

IART Hedge Fund Activity: Q2 2022 in Review

284 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2022, worth a combined $3.95B — down 16% from $4.71B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new IART positions and 23 closed out — a net gain of 12 holders — while 113 added to existing stakes and 95 trimmed.

The largest buyer was Two Sigma Advisers, adding an estimated $21.2M. The largest seller was Capital Research Global Investors, cutting an estimated $177M.

  • 284 institutional investors held Integra LifeSciences (IART) as of Q2 2022, up from 278 in Q1 2022.
  • Funds reported $3.95B of Integra LifeSciences stock for Q2 2022, down 16% quarter-over-quarter.
  • 35 funds opened new Integra LifeSciences positions in Q2 2022 and 23 closed out, a net change of +12 holders.
  • The largest Integra LifeSciences buyer in Q2 2022 was Two Sigma Advisers, an estimated $21.2M added.
  • The largest Integra LifeSciences seller in Q2 2022 was Capital Research Global Investors, an estimated $177M sold.

Based on aggregated 13F filings for Q2 2022.